Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Redefining extended-spectrum β-lactamases: balancing science and clinical need - authors' response

Giske, C. G., Sundsfjord, A. S., Kahlmeter, G., Woodford, N., Nordmann, P., Paterson, D. L., Canton, R. and Walsh, Timothy Rutland 2009. Redefining extended-spectrum β-lactamases: balancing science and clinical need - authors' response. Journal of Antimicrobial Chemotherapy 64 (1) , pp. 213-215. 10.1093/jac/dkp143

Full text not available from this repository.


Recently, we proposed a modified β-lactamase scheme for extended-spectrum β-lactamases (ESBLs) in recognition of the fact that this term is no longer sufficient to encapsulate accurately all β-lactamases possessing extended-spectrum activity and therefore requires refining.1 Our proposal was mainly based on a clinical perspective emphasizing the need for smooth communication between various groups of healthcare professionals. Accepting that such a proposal would be controversial, nonetheless we do not seek to polarize the ‘β-lactamase community’, but to stimulate dialogue on the merits of existing classifications and to explore necessary improvements. In reply to our proposal, Bush et al.2 raise a number of points that we wish to respond to:

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: ESBLs, AmpC, carbapenemases
Publisher: Oxford University Press
ISSN: 0305-7453
Last Modified: 04 Jun 2017 03:47

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item